When will CMS announce the addition of GLP-1 drugs for obesity to Part D?
As of Fri, 20 Nov 2026 14:15:14 UTC, Kalshi traders price Before Jan 20, 2029 (49.0%), Before Jan 1, 2028 (41.0%), Before Jan 1, 2027 (4.0%). The market has $22K in volume and closes on Sat, 27 Jan 2029.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before Jan 20, 2029 | 49.0% | 49.0¢ | 51.0¢ |
| Before Jan 1, 2028 | 41.0% | 41.0¢ | 59.0¢ |
| Before Jan 1, 2027 | 4.0% | 4.0¢ | 96.0¢ |
Market details
- Venue: Kalshi
- Volume: $22K
- Liquidity: $22K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before Jan 20, 2029:
If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 20, 2029, then the market resolves to Yes. GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part D sponsors through the Health Plan Management System. Where the White House or HHS makes the determination, the CMS document adopting it resolves this market, on the date of that document. The following do NOT resolve this market to YES: A CMS communication that discusses, studies or reports on such coverage. A proposed rule or a request for applications, which propose coverage rather than provide it. An action that considers the change and declines to make it. The Medicare GLP-1 Bridge, or extending or replacing it, because it sits outside the Part D benefit. An announcement covering only the Medicaid portion of the BALANCE Model. Coverage of a single drug, or of a subset of Part D enrollees, is sufficient. The announcement date governs, not the date coverage takes effect.
Sources
Related markets
- Venezuela leader end of 2026?
- Who will be Trump's next Press Secretary?
- Who will leave their role in the Trump administration this year?
- Will Trump buy at least part of Greenland?
- Will marijuana be rescheduled?
- Will the House impeach Trump?
More markets like this
- Which peptides will the FDA propose adding to the 503A Bulks List?
- Which vaccines will the CDC no longer recommend this year?
- Will CMS release any deferred Medicaid funds to California or Minnesota?
- Will Trump make IVF free?
- When will Dominic LeBlanc and Jamieson Greer meet?
- When will Erica Schwartz be confirmed as CDC director?
- When will FISA be reauthorized again?
- When will France announce a snap election?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.